CRISPR Therapeutics making headway to first commercial product

In this episode of #HealthWealth we are looking at exciting updates from CRISPR Therapeutics which provide insights into their activities to commercialize their first treatment for Sickle Cell Disease and Beta-Thalassemia likely much sooner than anticipated previously. This is potentially big news to investors in the gene editing industry.

Chapters:

0:00 Introduction

1:08 Collaboration Agreement for Manufacturing and Commercialization
3:56 Hiring of Chief Commercial Officer P. Drouet
4:26 CTX001 receiving designation as PRIME Medicine and Orphan Drug Status
5:13 PRIME Drug Designation
7:23 Orphan Drug Status
8:24 Look at Clinical Trial Status

Links:

[lilbroomstick]

Holding some pretty heavy bags w this one, but i knew i was investing for the future. Good luck crispr

[ronnieroberts]

7 months later still waiting for that 1st product